With more than 40 years’ experience, Insud Pharma has become an established, global group in the pharmaceutical industry, with a continuous growth and diversification. All of this to achieve the mission of providing accessible, effective, and high quality treatment, developing new and better, solutions and improving the health of millions of people all over, the world. Insud Pharma has a presence at every echelon of the chemical-pharmaceutical industry. Its activities are carried out through three synergistic business areas: industrial, branded and biotechnology.
Chemo is a global leader in R&D and manufacturing for over 100 value-added active pharmaceutical ingredients and more than 50 medicines with over 200 different product presentations. Its produces its own APls, as well as its own formulation patents for all major treatment areas. CHEMO’s facilities include five chemical plants in Italy, Spain, Argentina and India as well as four pharmaceutical facilities in Spain and one in India, all of which are fully compliant with GMP regulations and FDA and EMA quality standards. Coordinated out of its central headquarters, the company performs a wide range of commercial activities through its local offices, serving 1,115 customers in 96 countries worldwide, and is fully committed to active engagement with customers and to providing value in our business relationships.
Exeltis is a leading player in branded medicines. Now a top 5 name in Women´s Health, the company has expanded into other physician-driven therapeutic areas including Central Nervous System, Respiratory, Dermatology and Ophthalmology. In Women´s Health, the company is fully committed to innovation and partnership. Already a leader in contraception, the company has expanded its focus to encompass diseases with significant unmet patient needs, such as endometriosis and menopause. With a rapidly developing product catalogue, Exeltis serves patients and healthcare professionals all over the globe, accompanying women throughout every phase of their lives and investing heavily in R&D to bring new treatment options to market.
Exeltis has a direct presence in more than 40 countries in Europe, the Americas, Asia and Africa, and a global network of over 2,000 sales representatives.
mAbxience is a Spanish-based, full-fledged biotech company with a decade’s experience in developing and manufacturing biosimilar medicines. The company currently has two innovative development and manufacturing
facilities, located in Spain and Argentina. The company is built on a solid B2B model, which allows it to commercialize biosimilars around the world via a consolidated network of local partners, all of which are market leaders.
mAbxience is fully committed to quality and safety. With a passion for patient care and a mission to guarantee patient access and affordability, the mAbxience team works tirelessly to bring its biosimilars to all global markets. These high-quality biosimilars are developed using a state-of-the-art analytical platform in accordance with the strictest standards: fingerprint-like, biosimilars by design. ose to the organization:
EXELTIS is an exaltation of excellence, innovation and diversity.
